Author of

• 15382

  +

  P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15405

    +

    P3.04-023 - Exosomes and Their Potential for Detection of Lung Cancer (ID 831)

    09:30 - 09:30  |  Author(s): B. Sandfeld Paulsen
    • Abstract
    • Slides

    Background:
    A recent study showed that advanced lung adenocarcinoma patients have a distinct exosomal protein-profile compared to a matched group without cancer (Jakobsen et al., 2015, JEV). To improve the overall survival, it is however crucial to develop tools capable of detecting early stages of lung cancer as well. In addition, it is unsettled if different histologic subclasses result in distinct exosomal protein profiles. The aim of this study is to explore the potential of using exosomal proteins as biomarkers in lung cancer patients of all stages and of different histology histology.
    
    Methods:
    Plasma was isolated from patients suspected of having lung cancer. Patients diagnosed to be cancer free were defined as controls. Based on previous experiments a panel of 47 antibodies were selected for exosome-capture using a highly sensitive extracellular vesicle protein array (EV Array). 10 µl unpurified plasma was applied to the EV Array and captured exosomes were visualised by binding of biotin-conjugated CD9, CD63 and CD81 antibodies. The information from all 47 markers was investigated by multivariate analysis by partial least squares discriminant analysis (PLS-DA).
    
    Results:
    The study included 504 patients; 153 control patients and 351 patients with NSCLC (adenocarcinoma 70%, squamous cell 24%, other 6%). 51% had locally advanced or advanced disease and 49% had local disease. Multivariate analysis produced a combined marker model separating cancer patients from controls regardless of stage and histology. Area under the curve (AUC) was for each stage: I: 0.74 (0.68-0.82), II: 0.68 (0.57-0.79), III: 0.77 (0.62-0.91) and IV 0.79 (0.73-0.83). For all stages AUC was 0.755, CI (0.72-0.81) with sensitivity 0.70 and specificity 0.66. The accuracy of the test was 0.69.
    
    Conclusion:
    We demonstrate that the EV array is able to lung cancer in advanced as well as low stages regardless of histology.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.